Virtual screening for the discovery of bioactive natural products

Progress in Drug Research

Volumn 65, Issue , 2008, Pages 212-249

  Rollinger, Judith M ^a   Stuppner, Hermann ^a,b   Langer, Thierry ^a,b  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b Software Engineering and Consulting   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

NATURAL PRODUCT; BIOLOGICAL FACTOR; DRUG; LIGAND; PROTEIN;

BIOLOGICAL ACTIVITY; COMPUTER MODEL; COMPUTER PROGRAM; DATA BASE; DRUG MANUFACTURE; DRUG SCREENING; DRUG STRUCTURE; ETHNOPHARMACOLOGY; HIGH THROUGHPUT SCREENING; MACROMOLECULE; MATHEMATICAL ANALYSIS; METABOLITE; PHARMACOPHORE; PRIORITY JOURNAL; REVIEW; ANIMAL; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER INTERFACE; DISCRIMINANT ANALYSIS; DRUG DESIGN; HUMAN; MOLECULAR LIBRARY; PHARMACEUTICS; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; SYSTEM ANALYSIS;

ANIMALS; BIOLOGICAL FACTORS; COMPUTATIONAL BIOLOGY; DATABASES AS TOPIC; DISCRIMINANT ANALYSIS; DRUG DESIGN; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; PROTEIN CONFORMATION; PROTEINS; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; SYSTEMS INTEGRATION; TECHNOLOGY, PHARMACEUTICAL; USER-COMPUTER INTERFACE;

EID: 38449089793     PISSN: 0071786X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7643-8117-2_6     Document Type: Review

References (97)

1. Brown D, Superti-Furga G (2003) Rediscovering the sweet spot in drug discovery. Drug Discov Today 8: 1067-1077
2. Drews J (2003) Strategic trends in the drug industry. Drug Discov Today 8: 411-420
3. Smith A (2002) Screening for drug discovery: the leading question. Nature 418: 453-459
4. Strohl WR (2000) The role of natural products in a modern drug discovery program. Drug Disc Today 5: 39
5. Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70: 461-477
6. Harvey A (2000) Strategies for discovering drugs from previously unexplored natural products. Drug Disc Today 5: 294-300
7. Clardy J, Walsh C (2004) Lessons from natural molecules. Nature 432: 829-837
8. Jones WP, Chin YW, Kinghorn AD (2006) The role of pharmacognosy in modern medicine and pharmacy. Curr Drug Targets 7: 247-264
9. Dictionary of Natural Products provided by Chapman &Hall/CRC. Available at: http:// www.crcpress.com/shopping_cart/products/product_detail. asp?sku=C9150 (accessed in January 2007)
10. Tulp M, Bohlin L (2005) Rediscovery of known natural compounds: Nuisance or gold-mine? Bioorg Med Chem 13: 5274-5282
11. Sitte P, Weiler EW, Kadereit JW, Bresinsky A, Körner C (2002) Strasburger - Lehrbuch der Botanik, 35. Auflage, Spektrum Akademischer Verlag, Heidelberg, Berlin, 339-351
12. Balandrin M (1993) Plant-derived natural products in drug discovery and development: an overview. Amer Chem Soc Symposium Series No 534: 2-12
13. Cragg GM, Newman DJ, Snader KM (1997) Natural products in drug discovery and development. J Nat Prod 60: 52-60
14. Henkel T, Brunne RM, Muller H, Reichel F (1999) Statistical investigation into the structural complementarity of natural products and synthetic compounds. Angew Chem Int Ed 38: 643-647
15. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar M, Doyle M, FitzHugh W et al (2001) Initial sequencing and analysis of the human genome. Nature 409: 860-921
16. Deisenhofer J, Smith JL (2001) Proteins. Curr Opin Struc Biol 11: 701-702
17. Maggio ET, Ramnarayan K (2001) Recent developments in computational proteomics. Drug Disc Today 6: 996-1004
18. Potterat O, Hamburger M (2006) Natural products in drug discovery - concepts and approaches for tracking bioactivity. Curr Org Chem 10: 899-920
19. Pottereat O (2006) Targeted approaches in natural product lead discovery. Chimia 60: 19-22
20. Morrell J (1996) Mining information from databases for drug discovery. Book Abstr 211th ACS National Meeting CINF-052
21. Gasteiger J, Teckentrup A, Terfloth L, Spycher S (2003) Neural networks as data mining tools in drug design. J Phys Org Chem 16: 232-245
22. Xu J, Hagler A (2002) Chemoinformatics and drug discovery. Molecules 7: 566-600
23. Alvarez AJ, Shoichet B (2005) Virtual screening in drug discovery. Taylor & Francis, CRC-Press, Boca Raton
24. Langer T, Hoffmann RD (2006) Pharmacophores and pharmacophore searches. In: Methods and principles in medicinal chemistry Vol. 32, Wiley-VCH, Weinheim
25. Manly CJ, Louise-May S, Hammer JD (2001) The impact of informatics and computational chemistry on synthesis and screening. Drug Discov Today 6: 1101-1110
26. Langer T, Hoffmann RD (2001) Virtual screening: an effective tool for lead structure discovery? Curr Pharm Des 7: 509-527
27. Böhm HJ, Schneider G (2000) Virtual screening for bioactive molecules. Wiley, New York
28. Krovat EM, Steindl T, Langer T (2005) Recent advances in docking and scoring. Curr Comput-Aided Drug Des 1: 93-102
29. Abagyan R, Totrov M (2001) High-throughput docking for lead generation. Curr Opin Chem Biol 5: 375-382
30. Schneider G, Böhm HJ (2002) Virtual screening and fast automated docking methods. Drug Disc Today 7: 64-70
31. Shoichet BK, McGovern SL, Wei B, Irwin JJ (2002) Lead discovery using molecular docking. Curr Opin Chem Biol 6: 439-446
32. Stahl M, Rarey M (2001) Detailed analysis of scoring functions for virtual screening. J Med Chem 44: 1035-1042
33. Charifson PS, Corkery JJ, Murcko MA, Walters WP (1999) Consensus scoring: a method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J Med Chem 42: 5100-5109
34. Wang R, Wang S (2001) How does consensus scoring work for virtual library screening? An idealized computer experiment. J Chem Inf Comput Sci 41: 1422-1426
35. Liu B, Zhou J (2005) SARS-CoV protease inhibitors design using virtual screening method from natural products libraries. J Comp Chem 26: 484-490
36. Toney JH, Navas-Martin S, Weiss SR, Koeller A (2004) Sabadinine: a potential nonpeptide anti-severe acute-respiratory-syndrome agent identified using structure-aided design. J Med Chem 47: 1079-1080
37. Cozza G, Bonvini P, Zorzi E, Poletto G, Pagano MA, Sarno S, Donella-Deana A, Zagotto G, Rosolen A, Pinna LA et al (2006) Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J Med Chem 49: 2363-2366
38. Zhao L, Brinton RD (2005) Structure-based virtual screening for plant-based ERβ-selective ligands as potential preventative therapy against age-related neuro-degenerative diseases. J Med Chem 48: 3463-3466
39. Liu H, Li Y, Song M, Tan X, Cheng F, Zheng S, Shen J, Luo X, Ji R, Yue J et al (2003) Structure-based discovery of potassium channel blockers from natural products virtual screening and electrophysiological assay testing. Chem Biol 10: 1103-1113
40. Langer T, Hoffmann RD (2006) Pharmacophore modelling: applications in drug discovery. Exp Opin Drug Discov 1: 261-267
41. Doman TN, McGovern SL, Witherbee BJ, Kasten TP, Kurumbail R, Stallings WC, Connolly DT, Shoichet BK (2002) Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J Med Chem 45: 2213-2221
42. Samiulla DS, Vaidyanathan VV, Arun PC, Balan G, Blaze M, Bondre S, Chandrasekhar G, Gadakh A, Kumar R, Kharvi G et al (2005) Rational selection of structurally diverse natural product scaffolds with favorable ADME properties for drug discovery. Mol Divers 9: 131-139
43. Testa B (1984) Drugs? Drug research? Advances in drug research? Musings of a medicinal chemist. Adv Drug Res 13: 1-58
44. Smith DA, van de Waterbeemd H, Walker DK (2006) Pharmacokinetics and metabolism in drug design. 2nd Ed., Wiley-VCH, Weinheim
45. Avdeef A, Testa B (2002) Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques. Cell Mol Life Sci 59: 1681-1689
46. Feher M, Schmidt JM (2003) Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci 43: 218-227
47. Stahura F, Godden JW, Ling X, Bajorath J (2002) Distinguishing between natural products and synthetic molecules by descriptor Shannon entropy analysis and binary QSAR calculations. J Chem Inf Comput Sci 40: 1254-1252
48. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23: 3-25
49. Congreve M, Murray CW, Blundell TL (2005) Structural biology and drug discovery. Drug Disc Today 10: 895-907
50. Berman H, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H, Shindyalov I, Bourne P (2000) The protein data bank. Nucleic Acids Res 28: 235-242
51. Wolber G, Langer T (2000) LigandScout: 3D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 45: 160-169
52. Krovat EM, Frühwirth KH, Langer T (2005) Pharmacophore identification, in silico screening, and virtual library design for inhibitors of the human factor Xa. J Chem Inf Model 45: 146-159
53. Rella M, Rushworth C, Guy JL, Turner AJ, Langer T, Jackson RM (2006) Structure-based pharmacophore design and virtual screening for novel angiotensin converting enzyme 2 inhibitors. J Chem Inf Model 46: 708-716
54. Barreca ML, De Luca L, Iraci N, Rao A, Ferro S, Maga G, Chimirri A (2007) Structure-based pharmacophore identification of new chemical scaffolds as non-nucleoside reverse transcriptase inhibitors. J Chem Inf Model 47: 557-562
55. Schuster D, Laggner C, Steindl TM, Langer T (2006) Development and validation of an in silico P450 profiler based on pharmacophore models. Curr Drug Discov Technol 3: 1-48
56. Steindl TM, Schuster D, Laggner C, Langer T (2006) Parallel screening: a novel concept in pharmacophore modelling and virtual screening. J Chem Inf Model 46: 2146-2157
57. Steindl TM, Schuster D, Wolber G, Laggner C, Langer T (2007) High throughput structure-based pharmacophore modeling as a basis for successful parallel virtual screening. J Comput-aided Mol Des ASAP doi 10.1007/s10822-006-9066-y
58. Steindl TM, Schuster D, Laggner C, Chuang K, Hoffmann R, Langer T (2007) Parallel screening and activity profiling with HIV protease inhibitor pharmacophore models. J Chem Inf Model 47: 563-571
59. Nikolovska-Coleska Z, Xu L, Hu Z, Tomita Y, Li P, Roller PP, Wang R, Fang X, Guo R, Zhang M et al (2004) Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem 47: 2430-2440
60. Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X, Shi Y (2000) Structural basis of IAP recognition by Smac/DIABLO. Nature 408: 1008-1012
61. Rollinger JM, Hornick A, Langer T, Stuppner H, Prast H (2004) Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products. J Med Chem 47: 6248-6254
62. Langer T, Krovat EM (2003) Chemical feature-based pharmacophores and virtual library screening for discovery of new leads. Curr Opin Drug Discov Dev 6: 370-376
63. Schuster D, Maurer E, Laggner C, Nashev L, Wilckens T, Langer T, Odermatt A (2006) The discovery of new 11β-hydroxysteroid dehydrogenase Type 1 inhibitors by common feature pharmacophore modeling and virtual screening. J Med Chem 49: 3454-3466
64. Schuster D, Laggner C, Steindl TM, Palusczak A, Hartmann RW, Langer T (2006) Pharmacophore modeling and in silico screening for new P450 19 (aromatase) inhibitors. J Chem Inf Model 46: 1301-1311
65. Kurogi Y, Güner OF (2001) Pharmacophore modeling and three-dimensional database searching for drug design using Catalyst. Curr Med Chem 8: 1035-1055
66. Güner O, Clement O, Kurogi Y (2004) Pharmacophore modeling and three dimensional database searching for drug design using CATALYST: Recent advances. Curr Med Chem 11: 763-771
67. Füllbeck M, Huang X, Dumdey R, Frommel C, Dubiel W, Preissner R (2005) Novel curcumin-and emodin-related compounds identified by in silico 2D/3D conformer screening induce apoptosis in tumor cells. BMC Cancer 5: 97
68. Laggner C, Schieferer C, Fiechtner B, Poles G, Hoffmann RD, Glossmann H, Langer T, Moebius F (2005) Feature based pharmacophore models for sigma1 receptor, ERG2 and EBP. J Med Chem 48: 4754 -4764
69. Zupan J, Gasteiger J (1999) Neural networks in chemistry and drug design, 2nd Ed. Wiley-VCH, Weinheim
70. Wagner S, Hofmann A, Siedle B, Terfloth L, Merfort I, Gasteiger J (2006) Development of a structural model for NF-κB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem 49: 2241-2252
71. Sangma C, Chuakheaw D, Jongkon N, Saenbandit K, Nunrium P, Uthayopas P, Hannongbua S (2005) Virtual screening for anti-HIV-1 RT and anti-HIV-1 PR inhibitors from the Thai Medicinal Plants Database: A combined docking with neural networks approach. Comb Chem HTS 8: 417-429
72. Cherkasov A, Shi Z, Fallahi M, Hammond GL (2005) Successful in silico discovery of novel nonsteroidal ligands for human sex hormone binding globulin. J Med Chem 48: 3203-3213
73. Svetnik V, Liaw A, Tong D, Culberson C, Sheridan RP, Feuston BP (2003) Random Forest: a classification and regression tool for compound classification and QSAR Modeling. J Chem Inf Comput Sci 43: 1947-1958
74. Ehrman TM, Barlow DJ, Hylands PJ (2007) Virtual screening of Chinese herbs with random forest. J Chem Inf Model ASAP 10.1021/ci600289v
75. Kirchmair J, Laggner C, Wolber G, Langer T (2005) Comparative analysis of protein bound ligand conformations with respect to catalyst's conformational space subsampling algorithms. J Chem Inf Model 45: 422-430
76. Poroikov VV, Filimonov DM, Ihlenfeldt WD, Gloriozova TA, Lagunin AA, Borodina YV, Stepanchikova AV, Nicklaus MC (2003) PASS Biological activity predictions in the enhanced open NCI database browser. J Chem Inf Comput Sci 43: 228-236
77. Lu A, Liu B, Liu H, Zhou J, Xie G (2004) A traditional Chinese medicine plant-compound database aid its application for searching. Int Electron J Mol Des 3: 672-683
78. Füllbeck M, Michalsky E, Dunkel M, Preissner R (2006) Natural products: sources and databases. Nat Prod Rep 23: 347-356
79. Dunkel M, Füllbeck M, Neumann S, Preissner R (2006) SuperNatural: a searchable database of available natural compounds. Nucleic Acid Res 34: D678-683
80. Lei J, Zhou J (2002) A marine natural product database. J Chem Inf Comp Sci 42: 742-748
81. Rollinger JM, Haupt S, Stuppner H, Langer T (2004) Combining ethnopharmacology and virtual screening for lead structure discovery: COX-inhibitors as application example. J Chem Inf Comp Sci 44: 480-488
82. Bernard P, Berton JY, Chrétien JR (1999) Computer-aided molecular selection and design of natural bioactive molecules. Curr Opin Drug Disc Dev 2: 213-223
83. Ehrman TM, Barlow DJ, Hylands PJ (2007) Phytochemical databases of Chinese herbal constituents and bioactive plant compounds with known target specifities. J Chem Inf Model ASAP 10.1021/ci600288m
84. Rollinger JM, Langer T, Stuppner H (2006) Strategies for efficient lead structure discovery from natural products. Curr Med Chem 13: 1491-1507
85. Rollinger JM, Langer T, Stuppner H (2006) Integrated in silico tools to exploit the natural products' bioactivity. Planta Med 72: 671-678
86. Van de Waterbeemd H, Gifford E (2003) ADMET in silico modelling: towards prediction paradise? Nature Rev Drug Disc 2: 192-204
87. Rollinger JM, Bodensieck A, Seger C, Ellmerer EP, Bauer R, Langer T, Stuppner H (2005) Discovering COX-inhibiting constituents of Morus root bark: Activity-guided versus computer-aided methods. Planta Med 71: 399-405
88. Bernard P, Scior T, Didier B, Hibert M, Berthon JY (2001) Ethnopharmacology and bioinformatic combination for leads discovery: application to phospholipase A2 inhibitors. Phytochemistry 58: 865-874
89. Van de Waterbeemd H (2005) Which in vitro screens guide the prediction of oral absorption and volume of distribution? Bas Clin Pharmacol Toxicol 96: 162-166
90. Rollinger JM, Mock P, Zidorn C, Ellmerer EP, Langer T, Stuppner H (2005) Application of the in combo screening approach for the discovery of non-alkaloid acetylcholinesterase inhibitors from Cichorium intybus. Curr Drug Discov Techn 2: 185-193; Erratum (2006) 3: 89
91. Bajorath J (2002) Virtual screening in drug discovery: methods, expectations and reality. Curr Drug Disc March: 24-28
92. Bajorath J (2002) Integration of virtual and high-throughput screening. Nature Rev Drug Discovery 1 Nov: 882-894
93. Chimenti F, Cottiglia F, Bonsignore L, Casu L, Casu M, Floris C, Secci D, Bolasco A, Cimenti P, Granese A et al (2006) Quercetin as the active principle of Hypericum hircinum exerts a selective inhibitory activity against MAO-A: extraction, biological analysis, and computational study. J Nat Prod 69: 945-949
94. Rollinger JM, Schuster D, Baier E, Ellmerer EP, Langer T, Stuppner H (2006) Taspine: Bioactivity-guided isolation and molecular ligand-target insight of a potent acetylcholinesterase inhibitor from Magnolia x soulangiana. J Nat Prod 69: 1341-1346
95. Rognan D (2006) In silico screening of the protein structure repertoire and of protein families. Chemogenomics 109-131
96. Paul N, Kellenberger E, Bret G, Mueller P, Rognan D (2004) Recovering the true targets of specific ligands by virtual screening of the Protein Data Bank. Proteins 54 : 671-680
97. Nettles JH, Jenkins JL, Bender A, Deng Z, Davies JW, Glick M (2006) Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. J Med Chem 49: 6802-6810